Provided by Tiger Fintech (Singapore) Pte. Ltd.

Equillium Inc.

0.3626
-0.0064-1.73%
Post-market: 0.36260.00000.00%16:08 EDT
Volume:42.09K
Turnover:15.18K
Market Cap:12.95M
PE:-0.92
High:0.3690
Open:0.3677
Low:0.3510
Close:0.3690
Loading ...

Leerink says Equillium’s itolizumab news ‘disappointing but not surprising’

TIPRANKS
·
25 Apr

Equillium says FDA declines Breakthrough Therapy designation for itolizumab

TIPRANKS
·
24 Apr

Equillium Inc - Receives FDA Feedback on Itolizumab for Agvhd

THOMSON REUTERS
·
24 Apr

Equillium Inc - FDA Declines Breakthrough Therapy Designation for Itolizumab

THOMSON REUTERS
·
24 Apr

Equillium Announces Feedback from the U.S. Food and Drug Administration

Business Wire
·
24 Apr

EQ Resources Limited Appoints New Director

TIPRANKS
·
22 Apr

EQ Resources Strengthens Board with Industry Veteran Appointment

TIPRANKS
·
22 Apr

Equillium (EQ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Zacks
·
01 Apr

EQ Resources Says Non-Executive Chairman to Become Executive Chairman on Interim Basis

MT Newswires Live
·
01 Apr

EQ Resources Strengthens Leadership Team with Key Appointments

TIPRANKS
·
01 Apr

Revenues Working Against Equillium, Inc.'s (NASDAQ:EQ) Share Price Following 47% Dive

Simply Wall St.
·
31 Mar

Equillium Cut to Market Perform From Outperform by Leerink Partners

Dow Jones
·
28 Mar

Equillium Full Year 2024 Earnings: Beats Expectations

Simply Wall St.
·
28 Mar

Leerink Partners Downgrades Equillium to Market Perform From Outperform, Adjusts Price Target to $1 From $3

MT Newswires Live
·
28 Mar

Equillium Inc : Leerink Partners Cuts to Market Perform From Outperform

THOMSON REUTERS
·
28 Mar

Equillium downgraded to Market Perform from Outperform at Leerink

TIPRANKS
·
28 Mar

Equillium Inc : Leerink Partners Cuts Target Price to $1 From $3

THOMSON REUTERS
·
28 Mar

Gold Gains Over 1%; TD SYNNEX Shares Plunge After Downbeat Results

Benzinga
·
28 Mar

Equillium reports EQUATOR study did not improve complete, overall response rates

TIPRANKS
·
27 Mar

BRIEF-Equillium Reports Phase 3 Results Of Itolizumab For Acute Graft-Versus-Host Disease

Reuters
·
27 Mar